ILMN News and Press, Illumina Inc. From 02/02/26

2026-02-02 07:30:32 ET Cathie Wood's Ark Investment rotated money into high-conviction innovation themes, including AI, genomics, blockchain, and autonomous systems, while trimming exposure to mature biotech and established growth stocks.... Read the full article on Seeking Alpha ...

2026-01-30 09:34:08 ET More on Illumina Illumina: What Is Next In This Sequence? Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript ...

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy  ...

Illumina completes acquisition of SomaLogic PR Newswire Deeply expands leadership in proteomics and multiomics Combined capabilities bring high scalability, flexibility, and affordability into protein analysis  Combination leverages SomaScan with Illumina's NGS ec...

2026-01-28 12:16:27 ET I have been a long-time bull for Pacific Biosciences ( PACB ). The company is known for its long-read sequencing systems. The company sells these devices to labs and earns recurring revenue as they buy consumables (SMRT Cells, reagents, and kits). We can broad...

2026-01-28 11:30:15 ET More on healthcare stocks CMS Rates Proposal Shatters Health Insurance Stocks: What Investors Must Know (& Do) Insurers Brace For Extended 'Managed Retreat' Following 2027 MA Proposal XLV Vs. BME: Total Return Or Income, Which Healthcare St...

2026-01-27 06:15:54 ET More on ARK Invest ARKK: Buying Disruption At These Levels Is A Dangerous Game ARKW: Fourth Quarter Retreat May Preview A Volatile 2026 ARKK: Heads You Don't Win, Tails You Lose Moonshots: What investors need to know about the Artemis l...

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology PR Newswire The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healt...

2026-01-20 01:27:32 ET In the spring of 2023, I wondered what was up with the genes in the case of Illumina (ILMN) as the company suffered issues around its GRAIL (GRAL) acquisition. This uncertainty caused interest from activist investor Carl Icahn, looking to stir up thing...

2026-01-19 07:35:54 ET Cathie Wood’s ARK Invest ( ARKK ) deepened investment in AI chipmakers, gene-editing companies, and autonomous-driving developers while continuing to trim positions in Tesla ( TSLA ) and several mature tech companies and life...